Journal of Neuro-Oncology

, Volume 106, Issue 2, pp 377–382

Oligodendrogliomas in children

  • Kimberly M. Creach
  • Joshua B. Rubin
  • Jeffery R. Leonard
  • David D. Limbrick
  • Matthew D. Smyth
  • Ralph Dacey
  • Keith M. Rich
  • Joshua L. Dowling
  • Robert L. GrubbJr.
  • Gerald P. Linette
  • Allison A. King
  • Jeff M. Michalski
  • Tae Sung Park
  • Arie Perry
  • Joseph R. Simpson
  • David B. Mansur
Clinical Study–Patient Study

Abstract

Oligodendrogliomas are rare central nervous system (CNS) tumors in children. The purpose of this study was to identify prognostic factors for progression free survival (PFS) and overall survival (OS) in pediatric patients with oligodendrogliomas. We retrospectively analyzed clinical data on 37 pediatric patients with oligodendroglial tumors treated at Washington University. Kaplan–Meier method was used to calculate survival rates. Log-rank was used to detect the difference between survival curves. The median age was 11.1 years (range 10 months–18 years), and median follow-up was 4.5 years (range 2 months–30.5 years). The 5-year PFS and OS were 66.4 and 93.4%, respectively. Mixed histology was associated with worse OS compared to patients with pure oligodendroglioma, 5-year OS 77.6 versus 100% (P < 0.01). Patients who underwent gross total resection (GTR) experienced an improved 5-year PFS of 100% compared to 28.8% (P = 0.03) in patients treated with subtotal resection (STR) or biopsy alone. Age >3 years at diagnosis correlated with improved 5-year PFS, 33.3 versus 69.8% (P = 0.01). Neither post-operative chemotherapy nor radiation therapy correlated with improved outcome. GTR and age >3 years at diagnosis remained significant for improved PFS on multivariate analysis. There were no factors correlated with improved overall survival on multivariate analysis. Pediatric oligodendroglial tumors are associated with excellent OS; however, a third of patients developed progressive disease. Our data demonstrate that patients with less than GTR and <3 years at diagnosis are at increased risk for progression and may benefit from more aggressive therapy.

Keywords

Pediatric Adolescent Oligodendroglioma Oligoastrocytoma Glioma Prognostic factors 

References

  1. 1.
    Hoffman S, Propp JM, McCarthy BJ (2006) Temporal trends in incidence of primary brain tumors in the United States, 1985–1999. Neurooncology 8:27–37Google Scholar
  2. 2.
    Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG (2001) Trends in incidence of primary brain tumors in the United States, 1985–1994. Neurooncology 3:141–151Google Scholar
  3. 3.
    McCarthy BJ, Propp JM, Davis FG, Burger PC (2008) Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology 30:34–44PubMedCrossRefGoogle Scholar
  4. 4.
    Mork SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J (1985) Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63:881–889PubMedCrossRefGoogle Scholar
  5. 5.
    Armstrong GT, Conklin HM, Huang S, Srivastava D, Sanford R, Ellison DW, Merchant TE, Hudson MM, Hoehn ME, Robison LL, Gajjar A, Morris EB (2011) Survival and long-term health and cognitive outcomes after low-grade glioma. Neurooncology 13:223–234Google Scholar
  6. 6.
    Bowers DC, Mulne AF, Weprin B, Bruce DA, Shapiro K, Margraf LR (2002) Prognostic factors in children and adolescents with low-grade oligodendrogliomas. Pediatr Neurosurg 37:57–63PubMedCrossRefGoogle Scholar
  7. 7.
    Dohrmann GJ, Farwell JR, Flannery JT (1978) Oligodendrogliomas in children. Surg Neurol 10:21–25PubMedGoogle Scholar
  8. 8.
    Favier J, Pizzolato GP, Berney J (1985) Oligodendroglial tumors in childhood. Childs Nerv Syst 1:33–38PubMedCrossRefGoogle Scholar
  9. 9.
    Hirsch JF, Sainte Rose C, Pierre-Kahn A, Pfister A, Hoppe-Hirsch E (1989) Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg 70:568–572PubMedCrossRefGoogle Scholar
  10. 10.
    Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA (2005) Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol 109:387–392PubMedCrossRefGoogle Scholar
  11. 11.
    Peters O, Gnekow AK, Rating D, Wolff JE (2004) Impact of location on outcome in children with low-grade oligodendroglioma. Pediatr Blood Cancer 43:250–256PubMedCrossRefGoogle Scholar
  12. 12.
    Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, Wyatt RE, Rushing EJ, Bowers DC, Hynan LS, White CL 3rd (2003) Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 62:530–537PubMedGoogle Scholar
  13. 13.
    Razack N, Baumgartner J, Bruner J (1998) Pediatric oligodendrogliomas. Pediatr Neurosurg 28:121–129PubMedCrossRefGoogle Scholar
  14. 14.
    Rizk T, Mottolese C, Bouffet E, Jouvet A, Guyotat J, Bret P, Lapras C (1996) Cerebral oligodendrogliomas in children: an analysis of 15 cases. Childs Nerv Syst 12:527–529PubMedCrossRefGoogle Scholar
  15. 15.
    Tice H, Barnes PD, Goumnerova L, Scott RM, Tarbell NJ (1993) Pediatric and adolescent oligodendrogliomas. AJNR 14:1293–1300PubMedGoogle Scholar
  16. 16.
    Wang KC, Chi JG, Cho BK (1993) Oligodendroglioma in childhood. J Korean Med Sci 8:110–116PubMedGoogle Scholar
  17. 17.
    Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL (2007) Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol 83:1–8PubMedCrossRefGoogle Scholar
  18. 18.
    Dehghani F, Schachenmayr W, Laun A, Korf HW (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol 95:493–504PubMedCrossRefGoogle Scholar
  19. 19.
    Park HY, Lee NY, Park CK (2009) Risk factors of shallow anterior chamber other than hypotony after Ahmed glaucoma valve implant. J Glaucoma 18:44–48PubMedCrossRefGoogle Scholar
  20. 20.
    Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP (2003) Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65:259–266PubMedCrossRefGoogle Scholar
  21. 21.
    Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:1338–1345PubMedCrossRefGoogle Scholar
  22. 22.
    Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714PubMedCrossRefGoogle Scholar
  23. 23.
    Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA (1993) The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32:365–370 discussion 371 PubMedCrossRefGoogle Scholar
  24. 24.
    VandenBent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, Van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Onc 24:2715–2722CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Kimberly M. Creach
    • 1
  • Joshua B. Rubin
    • 2
  • Jeffery R. Leonard
    • 3
  • David D. Limbrick
    • 3
  • Matthew D. Smyth
    • 3
  • Ralph Dacey
    • 3
  • Keith M. Rich
    • 3
  • Joshua L. Dowling
    • 3
  • Robert L. GrubbJr.
    • 3
  • Gerald P. Linette
    • 4
  • Allison A. King
    • 2
  • Jeff M. Michalski
    • 1
  • Tae Sung Park
    • 3
  • Arie Perry
    • 5
  • Joseph R. Simpson
    • 1
  • David B. Mansur
    • 1
  1. 1.Department of Radiation Oncology and Mallinckrodt Institute of RadiologyWashington University School of MedicineSaint LouisUSA
  2. 2.Division of Pediatric Hematology and OncologyWashington University School of MedicineSaint LouisUSA
  3. 3.Department of Neurological SurgeryWashington University School of MedicineSaint LouisUSA
  4. 4.Division of OncologyWashington University School of MedicineSaint LouisUSA
  5. 5.Department of PathologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations